Investigational drugs for the treatment of endometriosis, an update on recent developments
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Endometriosis is a hormone-dependent benign chronic disease that requires a chronic medical therapy. Although currently available drugs are efficacious in treating endometriosis-related pain, some women experience partial or no improvement. Moreover, the recurrence of symptoms is expected after discontinuation of the therapies. Currently, new drugs are under intense clinical investigation for the treatment of endometriosis. AREAS COVERED: This review aims to offer the reader a complete and updated overview on new investigational drugs and early molecular targets for the treatment of endometriosis. The authors describe the pre-clinical and clinical development of these agents. EXPERT OPINION: Among the drugs under investigation, late clinical trials on gonadotropin-releasing hormone antagonists (GnRH-ant) showed the most promising results for the treatment of endometriosis. Aromatase inhibitors (AIs) are efficacious in treating endometriosis related pain symptoms but they cause significant adverse effects that limit their long-term use. New targets have been identified to produce drugs for the treatment of endometriosis, but the majority of these new compounds have only been investigated in laboratory studies or early clinical trials. Thus, further clinical research is required in order to elucidate their efficacy and safety in human.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ESHRE guideline: management of women with endometriosis
Dunselman, G. A. J., Vermeulen, N., Becker, C., Calhaz-Jorge, C., D'Hooghe, T., De Bie, B., Heikinheimo, O., Horne, A. W., Kiesel, L., Nap, A., et al. (2014) · Human Reproduction · doi:10.1093/humrep/det457 · Cited by 2,211
Endometriosis: pathogenesis and treatment
Vercellini, P., Viganò, P., Somigliana, E., & Fedele, L. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.255 · Cited by 1,940
Guerriero, S., Condous, G., van den Bosch, T., Valentin, L., Leone, F. P. G., Van Schoubroeck, D., Exacoustos, C., Installé, A. J. F., Martins, W. P., Abrao, M. S., et al. (2016) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.15955 · Cited by 900
Self-citationAromatase expression in endometriosis.
Noble, L. S., Simpson, E. R., Johns, A., & Bulun, S. E. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550748 · Cited by 566 · cited 1×
“Elevate levels of aromatase mRNA have been demonstrated in ectopic endometriotic implants [27].”
BackgroundTreatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
Taylor, H. S., Giudice, L. C., Lessey, B. A., Abrao, M. S., Kotarski, J., Archer, D. F., Diamond, M. P., Surrey, E., Johnson, N. P., Watts, N. B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700089 · Cited by 511 · cited 2×
“After promising findings from phase II studies, Elaris Endometriosis I-II trials (25) showed that both higher and lower doses of elagolix”
BackgroundChwalisz, K., Perez, M. C., DeManno, D., Winkel, C., Schubert, G., & Elger, W. (2005) · Endocrine Reviews · doi:10.1210/er.2005-0001 · Cited by 310
Estrogen-progestins and progestins for the management of endometriosis
Vercellini, P., Buggio, L., Berlanda, N., Barbara, G., Somigliana, E., & Bosari, S. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.10.022 · Cited by 243
Soysal, S. (2004) · Human Reproduction · doi:10.1093/humrep/deh035 · Cited by 227 · cited 2×
“Two randomized controlled trials demonstrated that the post-surgical administration of AIs as monotherapy or in combination with GnRH-as decreased more the risk of recurrence of endometriosis when compared with single GnRH-as or danazol [37,38].”
BackgroundTreatment of endometriosis with the antiprogesterone mifepristone (RU486)
Michael Kettel, L., Murphy, A. A., Morales, A. J., Ulmann, A., Baulieu, E. E., & Yen, S. S. C. (1996) · Fertility and Sterility · doi:10.1016/s0015-0282(16)58022-4 · Cited by 216
Casper, R. F. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.01.003 · Cited by 205 · cited 2×
“dominance in presence of progesterone resistance, leading to an eventual progression of endometriosis under therapy [164].”
Background
Cited by
Current and emerging treatment options for endometriosis
Ferrero, S., Evangelisti, G., & Barra, F. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1494154 · Cited by 152
“drugs have been tested in vitro and in animal models of endometriosis [10,11].”
BackgroundSelf-citationA comprehensive review of hormonal and biological therapies for endometriosis: latest developments
Barra, F., Grandi, G., Tantari, M., Scala, C., Facchinetti, F., & Ferrero, S. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1581761 · Cited by 69
Self-citationRekker, K., Tasa, T., Saare, M., Samuel, K., Kadastik, Ü., Karro, H., Götte, M., Salumets, A., & Peters, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123789 · Cited by 43
“Current endometriosis treatment strategies are rather general and mainly alleviate pain symptoms, but there are no specific approaches to cure the disease [2].”
BackgroundFerrari, F., Valenti, G., Forte, S., Ardighieri, L., Iraci Sareri, M., Barra, F., Sartori, E., & Odicino, F. (2021) · Journal of Obstetrics and Gynaecology Research · doi:10.1111/jog.14635 · Cited by 8
Self-citation
Metadata
- Authors
- Barra, F., Scala, C., Mais, V., Guerriero, S., & Ferrero, S.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2018-05-04
- Volume
- 27
- Issue
- 5
- Pages
- 445-458
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2801485675
- Cited by
- 57
- References
- 30
- FWCI
- 8.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Investigational drugs for the treatment of endometriosis, an update on recent developments. https://app.cochat.ai/papers/10.1080/13543784.2018.1471135
- The paper
- Barra, F., Scala, C., Mais, V., Guerriero, S., & Ferrero, S. (2018). Investigational drugs for the treatment of endometriosis, an update on recent developments. Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2018.1471135
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.